Promising pCR Rates with Neoadjuvant Durvalumab Plus Platinum-based Chemotherapy Combined with ADC for Patients with Resectable NSCLC By Ogkologos - July 29, 2025 595 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the NeoCOAST-2 study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR Using Aspirin to Prevent Breast Cancer Recurrence and Targeted Therapy for... February 14, 2022 Meteorologist Uses Sign Language To Tell All Of Her Weather Forecasts February 12, 2022 India’s First Homegrown CAR T-Cell Therapy Has Roots in NCI Collaboration February 7, 2024 Feasibility and Preliminary Efficacy Results of the Beat AML Study October 28, 2020 Load more HOT NEWS FDA Approves Axicabtagene Ciloleucel for Second-Line Treatment of Large B-Cell Lymphoma The link between Down syndrome and childhood leukaemia NGS Is Effective in Identifying Actionable Genetic Alterations for Investigational Targeted... Why Wearing Comfortable Clothes During Cancer Treatment Matters
